ULTRAGENYX PHARMA shares plummeted 45% to a record low after the company's rare disease drug failed to meet key targets in late-stage trials.

ULTRAGENYX PHARMA shares plummeted 45% to a record low after the company's rare disease drug failed to meet key targets in late-stage trials.